tbuckley/cabot-search huggingface dataset:
Long‐Term Outcome of Neuro‐Behçet's Disease
Authors: Nicolas Noel, Remy Bernard, Bertrand Wechsler, Matthieu Resche‐Rigon, Raphaël Depaz, Du Le Thi Huong Boutin, Jean‐Charles Piette, Aurélie Drier, Didier Dormont, Patrice Cacoub, David Saadoun
Journal: Arthritis & Rheumatology (2014)

To report the long-term outcome of neurologic involvement in patients with Behçet's disease (BD).We performed a retrospective analysis of 115 patients who fulfilled the international criteria for BD (57% male; median age 37 years [interquartile range (IQR) 30-46 years]) and had neuro-BD (NBD) after exclusion of cerebral venous thrombosis. Factors associated with relapse of NBD, inability to perform activities of daily living, and mortality were assessed.Seventy-eight patients (68%) presented with acute NBD and 37 (32%) presented with a progressive course. The HLA-B51 allele was carried by 49% of the patients. Overall, 46 of 115 patients (40%) had severe disability at baseline, represented by a Rankin score of ≥3. The 5- and 7-year event-free survival rates were 65% and 53%, respectively. In multivariate analysis, a positive HLA-B51 status was independently associated with the risk of NBD relapse, with an odds ratio (OR) of 3.6 (95% confidence interval [95% CI] 1.5-9.1). After a median followup of 73 months (IQR 59-102 months), 29 patients (25.2%) became dependent (were unable to perform activities of daily living) or died. Factors independently associated with poor outcome were paresis at onset (OR 6.47 [95% CI 1.73-24.23]) and location of inflammatory lesions at the brainstem on magnetic resonance imaging (OR 8.41 [1.03-68.43]). All 115 patients were treated with corticosteroids; 53 (46.1%) also took cyclophosphamide and 40 (34.8%) also took azathioprine. A trend toward longer event-free survival was observed in patients with severe NBD (i.e., with a Rankin score of ≥3 at onset) receiving intravenous cyclophosphamide compared with those receiving azathioprine (P = 0.06).Our findings indicate that NBD is a severe condition in which patients with the HLA-B51 allele appear to experience a worse prognosis.
Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress
Authors: Alicia M. Pickrell, Chiu-Hui Huang, Scott R. Kennedy, Alban Ordureau, Dionisia P. Sideris, Jake G. Hoekstra, J. Wade Harper, Richard J. Youle
Journal: Neuron (2015)
ACC/AHA/HRS 2006 Key Data Elements and Definitions for Electrophysiological Studies and Procedures
Authors: Alfred E. Buxton, Hugh Calkins, David J. Callans, John P. DiMarco, John D. Fisher, H. Leon Greene, David E. Haines, David L. Hayes, Paul A. Heidenreich, John M. Miller, Athena Poppas, Eric N. Prystowsky, Mark H. Schoenfeld, Peter J. Zimetbaum, Paul A. Heidenreich, David C. Goff, Frederick L. Grover, David J. Malenka, Eric D. Peterson, Martha J. Radford, Rita F. Redberg
Journal: Journal of the American College of Cardiology (2006)
Abstract P284: Social Engagement and Cardiovascular Risk Behaviors: The Multi-Ethnic Study of Atherosclerosis
Authors: Laura J Samuel, Cheryl R Dennison Himmelfarb, Teresa E Seeman, Sandra E Echeverria, Moyses Szklo, Ana V Diez-Roux
Journal: Circulation (2014)

Although social engagement is important to health behaviors, prior studies mostly considered only one of multiple different dimensions of it, with inconsistent results. Presence of countervailing or interacting influences of different types of social engagement may account for prior conflicting findings. This study identifies which dimensions of social engagement are associated with risk behaviors of smoking, low levels of physical activity, and a diet poor of fruit and vegetable intake. Cross-sectional data from 5004 participants, aged 45-84 from the Multi-Ethnic Study of Atherosclerosis was used. Social support was measured using the ENRICHD Social Support Instrument, loneliness with a three item instrument derived from the revised University of California at Los Angeles Loneliness Scale, and neighborhood social cohesion with the instrument from the Project on Human Development in Chicago Neighborhoods. Prevalence ratios of behaviors associated with standardized social engagement variables were modeled with Poisson regression, using robust standard errors. In unadjusted analyses, higher social support and neighborhood social cohesion were associated with slightly lower prevalence of smoking (prevalence ratio, PR=0.82, 95% CI: 0.77-0.87, and PR=0.91, 95% CI: 0.84-0.98, respectively) and slightly higher likelihood of achieving recommended levels of physical activity (PR=1.04, 95% CI: 1.02-1.07, and PR=1.05, 95% CI: 1.03-1.07, respectively). Higher loneliness was associated with slightly higher prevalence of smoking (PR=1.17, 95% CI: 1.10-1.24) and slightly less physical activity (PR=0.95, 95% CI: 0.93-0.98 ) . Associations of social support and loneliness with smoking, and associations of social support and neighborhood cohesion with physical activity, persisted after adjusting for individual characteristics. After further adjusting for all dimensions of social engagement, only neighborhood social cohesion remained associated with very slightly higher probability of achieving recommended physical activity levels (PR=1.03, 95% CI: 1.01, 1.05), and only social support remained associated with lower prevalence of smoking (PR=0.87, 95% CI: 0.81, 0.94) and higher probability of quitting, amongst those who had ever smoked (PR=1.03, 95% CI: 1.01, 1.06). Social support interacted with loneliness (p for interaction=0.001), such that these associations were present only amongst non-lonely individuals (PR=0.77, 95% CI: 0.69, 0.86). In fully adjusted models, no associations were found for fruit and vegetable intake. This study is among the first to simultaneously investigate several dimensions of social engagement and their interactions in relation to risk behaviors. Social support is more consistently associated with smoking than other dimensions of social engagement and this association appears to be modified by loneliness.
Afghanistan: Rebuilding a Health System
Authors: Gro Harlem Brundtland
Journal: JAMA (2002)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tobacco companies to make their research available on internet
Authors: Muhunthan Thillai
Journal: BMJ (2000)

Britain's major tobacco companies have agreed to make their medical research freely available on the internet. Appearing as witnesses to a select committee on health at the House of Commons last week, directors of some of the largest manufacturers, said that they had no problem with their archives being made more accessible.

“We would be prepared to make these documents publicly available on the internet,” said Peter Wilson, executive chairman of Gallaher Group.

Company directors from British American Tobacco, Philip …
The Ultrastructure of the Nuclear Envelope as Seen in Replicas from Normal and Neoplastic Nuclei
Authors: A. A. Barton
Journal: Cancer Research (1961)

Summary  A method of preparing carbon replicas of isolated liver and tumor nuclei is described which enables large areas of the nuclear surface to be examined. Two types of structure may be recognized: the first, large and irregular elevations thought to be due to nucleoli within the nucleus and, second, large numbers of small circular elevations 0.25 µ in diameter covering the whole surface. The appearance is compared with the results obtained by sectioning isolated nuclei and the tissues from which they were derived.
Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-seronegative patients
Authors: D Emilie, J Coumbaras, M Raphael, O Devergne, HJ Delecluse, C Gisselbrecht, JF Michiels, J Van Damme, T Taga, T Kishimoto
Journal: Blood (1992)
Seven Questions for Personalized Medicine
Authors: Michael J. Joyner, Nigel Paneth
Journal: JAMA (2015)

Personalized or precision medicine maintains that medical care and public health will be radically transformed by prevention and treatment programs more closely targeted to the individual patient. These interventions will be developed by sequencing more genomes, creating bigger biobanks, and linking biological information to health data in electronic medical records (EMRs) or obtained by monitoring technologies. Yet the assumptions underpinning personalized medicine have largely escaped questioning. In this Viewpoint, we seek to stimulate a more balanced debate by posing 7 questions for the advocates of personalized medicine.
First Attending Rounds
Authors: N L Greengold
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Passive sensitization and histamine release of basophils
Authors: H. Nolte, M. Poulsen, P. O. Schiøstz, P. Stahl Skov
Journal: Allergy (1990)

This study had two purposes. First, to examine a possible functional heterogeneity of IgE regulating basophil histamine release and the effect of using two different donor cells for passive sensitization experiments. Second, to investigate basophils not releasing histamine to anti‐tgE by stimulating protein kinase C with the addition of the phorbol‐ester, TPA. In consecutive experiments responding donor basophils were passively sensitized with plasma from non‐responding subjects. Thus, the first set of experiments included passive sensitization of acid treated donor basophils from one atopic and one non‐atopic patient with plasma from 29 children with exogenous asthma to grass pollen, cat dander, or dust mites. Different secretagogues (anti‐IgE, Concanavalin A, and N‐formyl‐methionyl‐leucyl phenylalanine) induced different histamine release responses due to a cellular property of the basophils not related to the type of IgE bound to the cell membrane. It was demonstrated that the allergen‐induced histamine release did not depend on the extract or type of IgE when the biological activity of each extract and serum‐specific IgE levels were similar. However, the atopic donor cells released significantly ( P &lt;0.05) more histamine than non‐atopic donor cells. Thus, histamine release depends on the type of secretagogues and a cellular property which is maybe influenced by the presence of serum factors and a certain type of IgE in the serum of atopics. The second set of experiments included 10 patients (6 atopics and 4 non‐atopics) with non‐histamine releasing basophils. In the presence of 10 ng/ml TPA, however, seven of 10 patients released histamine at anti‐IgE challenge. Three months later two additional patients became responsive in the presence of TPA. By passive sensitization of responding donor basophils the non‐responding patients were shown to possess functionally intact IgE. Thus, the discrepancies sometimes observed between clinical symptoms, serological IgE‐antibody measurements and histamine release testing in allergic patients may be related to a cellular property of basophils.
Study Reveals Consistent Ebola Virus Mutation Rate Between Outbreaks
Authors: Tracy Hampton
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Web Site for Asthma ManagementGenetic MilestonePatient Privacy WorriesComplications After SurgeryWeb Site for Asthma ManagementGenetic MilestonePatient Privacy WorriesComplications After Surgery
Authors: Joan Stephenson
Journal: JAMA (1999)

Physicians seeking the most up-to-date information about asthma diagnosis and treatment now have access to a new Web site with virtually all the scientific literature on chronic asthma ever published, according to the National Heart, Lung, and Blood Institute (NHLBI).
759. The DNA Minor Groove Binding Agents Hoechst 33258 and 33342 Enhance Recombinant Adeno-Associated Virus (rAAV) Transgene Expression
Authors: Lina Li, Linda Yang, Robert M. Kotin
Journal: Molecular Therapy (2004)

Recombinant adeno-associated viruses (rAAV) are commonly used in pre-clinical and clinical gene transfer studies. The relatively slow kinetics of rAAV transgene expression, however, complicates in vitro and in vivo experiments. Accelerating the kinetics of rAAV transgene expression would extend the applications of rAAV for gene transfer and facilitate the determination of vector biological activity in vitro. We found that the DNA minor groove binding agents, Hoechst 33258 and 33342, enhance rAAV gene expression. Hoechst 33258 or 33342 increase both the level of reporter gene expression and the population of transgene expressing cells. We found that Hoechst 33258 and 33342 augment rAAV gene expression in different cell types and in a concentration dependent manner. Hoechst 33258 or 33342 enhanced gene expression for rAAV-1, rAAV-2 and rAAV-5. Hoechst 33258 and 33342 mediated enhancement of rAAV gene expression correlated with an increase in S phase and G2/M phases of the cell cycle. Our data revealed that two different, although related, DNA binding drugs effect rAAV gene expression in a similar manner, suggesting that a common pathway is involved. Our results suggest that Hoechst 33258 and 33342 are potential enhancer drugs for the gene expression and might be useful for gene therapy applications.
THE ASSOCIATION OF TYPE SPECIFIC HEMOLYTIC STREPTOCOCCI WITH ACUTE GLOMERULONEPHRITIS 1
Authors: Arthur R. Wertheim, John D. Lyttle, Emily N. Loeb, David P. Earle, Beatrice C. Seegal, David Seegal, Elizabeth L. Jost, Grace Davis, Mollie Saltzman
Journal: Journal of Clinical Investigation (1953)
Landscape With Transplanted Beasts
Authors: Woods Nash
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Arthritis Medications and Cardiovascular Events—Reply
Authors: Eric J. Topol
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 64: Targeting immune checkpoints: using a big data approach for their identification, prioritization and application
Authors: Sheetal Kaw, Sanatan Upmanyu, Himani Sharma, Krishnan Nandabalan
Journal: Cancer Research (2015)

Abstract Tumor cells have long been known to successfully evade immune surveillance mechanisms.In order to curtail the tumor progression as well as to develop effective therapeutic anti-tumor strategies, key immune regulators,or so-called immune checkpoints, havebeen recognizedas playing an important role. To prevent excess tissue damage,immune checkpoints that refer to a number of inhibitory players involved in immune responses,are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses.Therapies targeting such immune checkpoints such as CTLA-4 and PD-1 have shown great clinical successas they boost the already existing immune response working against the tumorprogression. To identify novel immune checkpoints it becomes crucial to comprehensively analyze the wealth of existing knowledge regarding key signaling pathways, theircross-talk with immune regulators, protein expression profiles in tumor tissues, and patient outcomes data. These data silos require a big data analytics approach to successfully hypothesize, query and derive meaningful conclusions from this data. With a proprietary big data analytics platform PharmGPS™, we have identified a number of immune checkpoints that have clear therapeutic potential for solid tumor regenesis. First, second and third degree associations between tumorigenic pathways and immune checkpoints were identified and preliminary findings will be presented. Citation Format: Sheetal Kaw, Sanatan Upmanyu, Himani Sharma, Krishnan Nandabalan. Targeting immune checkpoints: using a big data approach for their identification, prioritization and application. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 64. doi:10.1158/1538-7445.AM2015-64